CRISPR Therapeutics AG (CRSP)
Nasdaq: CRSP · Biological Products, (No Diagnostic Substances) · Zug · filing with the SEC since 2016
Who owns CRISPR Therapeutics AG
As filed with the SECHolders of 5% or more
4
ARK Investment Management LLC holds 11.8% of Common Stock, as its SCHEDULE 13G/A filed Apr 30, 2026 says.
Directors and officers
16
report now, of 31 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
ARK Investment Management LLC
SCHEDULE 13G/A · filed Apr 30, 2026 · Common Stock · 10.8% in Nov 4, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 6.9% in Jul 17, 2025
Orbis Investment Management Ltd
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 6.3% in May 15, 2026
Capital World Investors
SCHEDULE 13G · filed May 14, 2026 · Common Stock
Capital International Investors
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Stock · reported falling below 5%, from 7.4% in May 13, 2025
What CRSP reports owning in othersstakes of 5% or more, and other ties
4 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 12, 2026.
Insider tradesForm 4
30sales
0purchases
13sales on a scheduled plan
6people selling
$17.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 47 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kulkarni Samarth | Chief Executive Officer | 9 | $9.6M | 3 | 0 | $0 |
| Prasad Raju | Chief Financial Officer | 10 | $5.1M | 7 | 0 | $0 |
| Kasinger James R. | General Counsel and Secretary | 7 | $1.4M | 2 | 0 | $0 |
| Behbahani Ali | director | 1 | $800,000 | 0 | 0 | $0 |
| George Simeon | director | 1 | $700,000 | 1 | 0 | $0 |
| Patel Naimish | Chief Medical Officer | 2 | $400,000 | 0 | 0 | $0 |